Pfizer Inc. (NYSE:PFE) Shares Sold by Schulhoff & Co. Inc.

Schulhoff & Co. Inc. decreased its position in Pfizer Inc. (NYSE:PFE) by 8.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,800 shares of the biopharmaceutical company’s stock after selling 4,536 shares during the quarter. Schulhoff & Co. Inc.’s holdings in Pfizer were worth $1,242,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Swedbank AB lifted its position in shares of Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Pallas Capital Advisors LLC lifted its holdings in Pfizer by 54.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 25,711 shares of the biopharmaceutical company’s stock worth $736,000 after buying an additional 9,102 shares in the last quarter. Fidelis Capital Partners LLC boosted its position in Pfizer by 5.2% in the 3rd quarter. Fidelis Capital Partners LLC now owns 25,835 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 1,267 shares during the period. Great Diamond Partners LLC purchased a new position in Pfizer in the 3rd quarter valued at approximately $203,000. Finally, First Trust Direct Indexing L.P. grew its stake in shares of Pfizer by 15.4% in the third quarter. First Trust Direct Indexing L.P. now owns 82,585 shares of the biopharmaceutical company’s stock worth $2,390,000 after acquiring an additional 11,026 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. UBS Group decreased their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $26.09 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm’s fifty day simple moving average is $26.35 and its 200-day simple moving average is $27.35. The stock has a market cap of $147.83 billion, a PE ratio of 18.50, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the company earned $0.10 EPS. The company’s quarterly revenue was up 24.7% on a year-over-year basis. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.59%. The ex-dividend date of this dividend is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.